Lamivudine; nevirapine; zidovudine - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for lamivudine; nevirapine; zidovudine and what is the scope of patent protection?
Lamivudine; nevirapine; zidovudine
is the generic ingredient in one branded drug marketed by Micro Labs and is included in one NDA. Additional information is available in the individual branded drug profile pages.There are seven tentative approvals for this compound.
Summary for lamivudine; nevirapine; zidovudine
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 45 |
DailyMed Link: | lamivudine; nevirapine; zidovudine at DailyMed |
Recent Clinical Trials for lamivudine; nevirapine; zidovudine
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Johns Hopkins University | Phase 1/Phase 2 |
The Aurum Institute NPC | Phase 1/Phase 2 |
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Phase 4 |
Generic filers with tentative approvals for LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 150MG; 200MG; 300MG | TABLET; ORAL |
⤷ Sign Up | ⤷ Sign Up | 150MG; 200MG; 300MG | TABLET; ORAL |
⤷ Sign Up | ⤷ Sign Up | 30MG; 50MG; 60MG | TABLET, FOR SUSPENSION; ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Anatomical Therapeutic Chemical (ATC) Classes for lamivudine; nevirapine; zidovudine
US Patents and Regulatory Information for lamivudine; nevirapine; zidovudine
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Micro Labs | LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE | lamivudine; nevirapine; zidovudine | TABLET;ORAL | 205626-001 | Aug 13, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |